PEPTIDE GUIDE

What Is HGH Fragment 176-191?

HGH Fragment 176-191 is a laboratory-made peptide that copies the final 16 amino acids of human growth hormone. HGH means human growth hormone. The numbers identify positions 176 through 191 in the natural 191-amino-acid protein.

Researchers studied short fragments from this end of growth hormone in the 1970s and 1980s because they appeared to affect glucose and insulin in rats. Later animal work focused more heavily on the neighbouring 15-amino-acid fragment HGH 177-191 and on modified descendants called AOD-9401 and AOD-9604. These names are often treated as though they mean the same thing. They do not.

The exact HGH 176-191 fragment has no established human clinical use. We did not locate a direct controlled human trial of this exact 16-residue sequence. Claims about fat loss, muscle preservation, recovery or glucose safety are therefore not supported by direct clinical evidence. Even the related AOD-9604 development programme did not establish a successful obesity treatment.

Research statusUnapproved growth-hormone fragment without direct human clinical evidence
Peptide typeSixteen-residue C-terminal growth-hormone fragment
Human evidenceNo direct controlled clinical trial located
ApprovalNot an approved medicine
Last reviewedSeptember 2026
THE SHORT ANSWER

HGH Fragment 176-191 is the 16-amino-acid tail of human growth hormone. It is not full growth hormone, does not act as a growth hormone secretagogue and has not been shown to raise a person's growth hormone or IGF-1. The exact fragment appeared in rat metabolism research in 1978, where a single experimental exposure caused a short-lived rise in blood glucose, a longer rise in insulin and reduced insulin sensitivity. Later fat-metabolism studies usually tested the 15-residue HGH 177-191 fragment or modified molecules such as AOD-9401 and AOD-9604. Those results cannot automatically be assigned to HGH 176-191. No direct human clinical trial of the exact fragment was located, and it is not an FDA-approved or EMA-authorised medicine. The World Anti-Doping Agency explicitly prohibits HGH 176-191 in sport.

What exactly is HGH Fragment 176-191?

Human growth hormone is a protein containing 191 amino acids. A fragment is a shorter piece that copies a continuous part of a larger protein. HGH Fragment 176-191 copies the final 16 positions, beginning with phenylalanine at position 176 and ending with phenylalanine at position 191.

Its one-letter sequence is FLRIVQCRSVEGSCGF. Written out, that is phenylalanine, leucine, arginine, isoleucine, valine, glutamine, cysteine, arginine, serine, valine, glutamic acid, glycine, serine, cysteine, glycine and phenylalanine.

The two cysteines can form a disulphide bond. A disulphide bond is a link between the sulphur atoms of two cysteine residues. In the isolated fragment, that link creates a small loop. The shape may affect activity, stability and how the material behaves during testing.

Chemical databases report a molecular formula of C78H123N23O22S2 and a molecular mass of about 1,799 daltons for the disulphide-bonded peptide. A dalton is a unit used for the mass of atoms and molecules.

Somatotropin is another name for growth hormone, so somatotropin (176-191) is a chemical name for the same fragment. HGH 176-191 and hGH 176-191 are different capitalisations of the same description. A label may also say GH Fragment 176-191.

The name alone does not establish whether a material is the oxidised, disulphide-bonded form, a reduced linear form, a salt or a mixture. It also does not establish purity, sterility, concentration or stability.

Is HGH Fragment 176-191 the same as human growth hormone?

No. Full human growth hormone has 191 amino acids and a folded three-dimensional structure made from several connected helices. A helix is a coiled section of a protein. The full protein interacts with the growth hormone receptor using surfaces created by distant parts of the folded molecule.

HGH Fragment 176-191 contains only the final 16 amino acids. It cannot reproduce the complete shape and receptor contacts of full growth hormone. A small fragment may have its own effects, no effect or effects that move in a different direction from the parent protein.

HGH Fragment 176-191 is also not a growth hormone secretagogue. A secretagogue prompts the pituitary gland to release stored growth hormone. Compounds such as GHRP-2, GHRP-6, hexarelin and ipamorelin activate the ghrelin receptor. HGH Fragment 176-191 is a structural fragment of growth hormone and is not supported as a ghrelin-receptor agonist.

There is no direct human evidence showing that the exact fragment raises growth hormone or insulin-like growth factor 1, shortened to IGF-1. IGF-1 is a hormone involved in normal growth and tissue maintenance. It is often discussed alongside growth hormone, but its involvement should not be assumed from the fragment's name.

Is HGH Fragment 176-191 the same as HGH 177-191?

No. HGH 176-191 begins one amino acid earlier.

  • HGH 176-191 contains 16 residues and begins with phenylalanine.
  • HGH 177-191 contains 15 residues and begins with leucine.

One residue may look like a small difference, but peptide activity depends on exact sequence, shape and chemical form. The two compounds also have different molecular masses. Evidence for one should not be assigned to the other without direct comparison.

This matters because much of the research commonly presented under the HGH Fragment 176-191 name actually tested HGH 177-191. The 1993 rat fat-pad paper tested the 15-residue sequence. The 1994 obese-mouse paper also tested HGH 177-191. They are relevant to the history of C-terminal growth-hormone-fragment research, but they are not direct evidence for a commercial material labelled HGH 176-191.

Is it the same as AOD-9401 or AOD-9604?

No. The four names describe related but different molecules.

NameStructureMain evidence
HGH 176-191Natural growth-hormone positions 176 to 191, beginning with phenylalanineDirect older rat metabolism study; no direct human clinical trial located
HGH 177-191Natural positions 177 to 191, beginning with leucineOlder rat tissue and obese-mouse studies
AOD-9401A research name used for cyclic HGH 177-191Animal and laboratory fat-metabolism work
AOD-9604Tyrosine added to the front of HGH 177-191, producing Tyr-HGH 177-191Animal studies and a human obesity programme that did not establish efficacy

AOD stands for anti-obesity drug in this development history. AOD-9604 contains 16 residues, as does HGH 176-191, but the first residue is tyrosine rather than phenylalanine. Matching length does not make the sequences identical.

The human AOD-9604 programme is useful negative context. It shows that encouraging animal fat-metabolism findings for a related fragment did not guarantee a useful human weight-loss treatment. It cannot establish the safety or ineffectiveness of every HGH 176-191 material, but it sets a high bar for claims that the exact fragment is already proven.

Our separate AOD-9604 guide examines that molecule and its clinical programme in detail.

What is HGH Fragment 176-191 made from?

The fragment is assembled from 16 amino-acid derivatives. These building blocks correspond to the natural L-amino acids found at the end of human growth hormone:

  • Two phenylalanines.
  • Two arginines.
  • Two valines.
  • Two cysteines.
  • Two serines.
  • Two glycines.
  • One leucine.
  • One isoleucine.
  • One glutamine.
  • One glutamic acid.

The raw amino acids may have familiar names, but peptide manufacture uses chemically protected forms. Protective groups temporarily cover reactive parts so that each bond forms in the intended place.

The laboratory-made fragment is not normally cut from human pituitary glands, blood or recombinant growth hormone. It can be assembled directly from chemical raw materials. The final amino-acid order copies the human sequence, but the manufacturing route and finished product are artificial.

How is HGH Fragment 176-191 synthesised and manufactured?

The usual chemical route is solid-phase peptide synthesis. One end of the future peptide is attached to an insoluble resin bead. Protected amino-acid derivatives are then added one at a time, beginning at the end of the sequence and building backwards.

Each cycle removes a temporary protective group, activates the next amino acid and forms a peptide bond. Coupling reagents help drive that reaction. Solvents wash away unused building blocks and reaction by-products. Sixteen residues require repeated cycles, and incomplete coupling at any stage can create a shorter deletion sequence.

The cysteines need particular control. Their sulphur-containing side chains are protected during chain assembly. After the peptide is released from the resin and the temporary groups are removed, controlled oxidation can create the disulphide bond between the two cysteines. Oxidation here means formation of the sulphur-to-sulphur link, not simply unwanted damage.

If oxidation is incomplete, the material may contain reduced linear peptide as well as the intended cyclic form. If cysteines link between separate peptide molecules, dimers or larger aggregates can form. A dimer is two peptide molecules joined together. These forms can have different activity and immune properties.

The raw materials include protected versions of all 16 amino acids, the resin, coupling reagents, bases, solvents, cleavage chemicals and reagents used to control disulphide formation. Poor-quality raw materials can introduce the wrong amino acid, unwanted stereochemistry, metals or other contaminants.

After assembly and cleavage from the resin, the crude mixture requires purification. Preparative high-performance liquid chromatography, shortened to HPLC, can separate the main peptide from many impurities. Analytical HPLC estimates the proportions of separated components. Mass spectrometry measures mass-to-charge patterns and can support confirmation of the expected molecular mass.

Mass and a single HPLC peak do not prove that the disulphide bond is in the intended form. Peptide mapping, reduction studies or other structural methods may be needed. Amino-acid analysis can check composition, while tests designed for stereochemistry examine whether each building block has the correct three-dimensional orientation.

The purified material may be converted to a salt and freeze-dried. Freeze-drying removes water at low temperature and reduced pressure. It does not make the product sterile, remove endotoxins or prove concentration. Endotoxins are inflammatory bacterial components that can remain even when living bacteria are absent.

For any product intended for injection, validated controls would also be needed for sterility, endotoxins, particles, amount, container closure and stability. Stability work should examine oxidation, disulphide reshuffling, aggregation and chemical breakdown across time.

Manufacturing quality cannot repair an evidence gap. A correctly made research peptide would still lack direct human clinical evidence for fat loss or other claimed benefits.

When was HGH Fragment 176-191 first documented?

Research on the end of human growth hormone grew out of a larger effort to identify which parts of the full protein controlled growth, fat metabolism and glucose regulation.

In the 1970s, researchers used chemical digestion and synthesis to examine growth-hormone fragments. A 1978 paper directly included synthetic HGH 176-191 among six C-terminal fragments tested in normal rats. C-terminal means the end of a peptide or protein carrying the carboxyl group.

The 1978 experiment found that fragments containing positions 178 to 191, including HGH 176-191, caused a short-lived rise in blood glucose and a more sustained rise in insulin. They also reduced insulin sensitivity during an intravenous insulin-tolerance test. An insulin-tolerance test measures how blood glucose responds after insulin is given under controlled conditions.

Work published in 1979 described solid-phase synthesis and activity of HGH 177-191, 178-191 and 179-191. Studies through the early 1980s examined liver glycogen, muscle glycogen and insulin release in rat tissues. Glycogen is a stored form of glucose in liver and muscle.

Interest shifted in the 1990s towards fat metabolism and obesity. The molecule in most of those papers was HGH 177-191, not HGH 176-191. Researchers then developed the AOD molecules. AOD-9604 entered human obesity studies, but the programme did not establish an effective weight-loss medicine.

Recent commercial attention has returned to the HGH 176-191 name. That attention is not accompanied by a comparable modern human clinical record.

YearDevelopment
1970sResearchers separated and synthesised regions of human growth hormone to map their effects
1978HGH 176-191 was directly tested with related fragments in normal rats
1979 to 1983HGH 177-191 and shorter fragments were studied for glucose, insulin and glycogen effects
1993HGH 177-191 reduced fat synthesis in rat tissue but did not significantly increase fat breakdown
1994HGH 177-191 reduced weight gain and fat mass in obese mice
Late 1990s to 2000sAOD-9401 and AOD-9604 were developed from HGH 177-191 research
2000sAOD-9604 human obesity development did not establish efficacy
Current positionNo direct controlled human clinical trial of exact HGH 176-191 was located

How might C-terminal growth-hormone fragments work?

There is no settled human mechanism for HGH Fragment 176-191. Most proposed explanations come from animal tissues, whole-animal models or studies of related fragments.

Full growth hormone can influence growth, protein turnover, fat metabolism and glucose regulation. Researchers asked whether separate regions of the protein carried separate signals. The C-terminal fragments were initially associated with glucose-raising and insulin-antagonistic activity. Insulin-antagonistic means making insulin less effective at lowering blood glucose.

Later work with HGH 177-191 reported antilipogenic activity in rat fat tissue. Antilipogenic means reducing the creation or storage of new fat. This is different from lipolytic, which means increasing the breakdown of stored fat. In the 1993 paper, HGH 177-191 reduced fat synthesis but did not significantly increase glycerol release, the study's measure of fat breakdown.

Other experiments found changes in glucose transport into rat fat cells, liver glycogen metabolism, muscle glycogen synthase and insulin release from isolated rat pancreatic islets. Glycogen synthase is an enzyme that helps build glycogen. Pancreatic islets are groups of cells in the pancreas that include insulin-producing beta cells.

These findings do not form a simple safe fat-loss mechanism. Reduced insulin sensitivity and higher glucose are potentially adverse metabolic effects. Changes in fat synthesis in isolated tissue may not outweigh appetite, energy expenditure, liver metabolism and other processes in a whole human body.

The exact HGH 176-191 fragment also cannot be assumed to have every action reported for HGH 177-191 or AOD-9604. Direct comparisons would be required.

What did the direct 1978 HGH 176-191 study find?

The study used normal rats, not people. Researchers tested synthetic fragments corresponding to growth-hormone positions 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191.

Each fragment was given once at 5 nanomoles per kilogram of body weight. A nanomole is one billionth of a mole, a unit that counts molecules. Reporting in moles allows compounds of different molecular mass to be compared by molecule number.

HGH 176-191 and three other fragments caused a short-lived increase in blood glucose and a more sustained increase in plasma insulin. Plasma is the liquid portion of blood. The fragments containing the 178-191 sequence also reduced insulin sensitivity in intravenous insulin-tolerance tests.

The two shortest fragments, HGH 179-191 and HGH 180-191, were inactive in the systems tested. The investigators concluded that the active information needed a minimum sequence and the correct physical configuration.

This result is direct evidence for biological activity of HGH 176-191 in rats. It is not evidence of fat loss in people. The direction of the glucose finding also conflicts with descriptions of the fragment as metabolically neutral or neatly separated from the glucose effects of growth hormone.

What did the later glucose and insulin studies find?

Most of the later work used HGH 177-191 or related fragments.

An isolated rat-islet study found that HGH 177-191 increased glucose-stimulated insulin release in a concentration-related way. The peptide did not stimulate insulin release without glucose. Isolated islets remove the influence of the nervous system, liver and other organs, so the result describes a local laboratory response.

Rat studies examined liver and muscle glycogen. HGH 177-191 changed the active form of glycogen synthase in the liver and muscle. These biochemical changes supported the idea that the end of growth hormone could influence glucose storage.

Other work tested shortened or chemically reduced fragments and found that the disulphide bond was not always essential for the measured insulin-antagonistic effect. That does not mean all chemical forms are interchangeable. It shows that one animal assay did not require the bond under those conditions.

The evidence is old, preclinical and spread across different fragments and forms. It does not define what repeated HGH 176-191 exposure would do to fasting glucose, HbA1c or diabetes risk in people. HbA1c is a blood test that reflects average glucose over roughly the previous two to three months.

What did the fat-metabolism studies find?

The most cited fat findings belong mainly to HGH 177-191.

In a 1993 laboratory study, researchers used fat pads from rats treated with the 15-residue peptide. HGH 177-191 reduced lipogenesis, which is the creation and storage of new fat. The effect was described as similar to that of full growth hormone in that experimental system.

The same paper did not find a significant lipolytic effect when it measured glycerol release. Glycerol is released when stored triglycerides are broken down, so it is often used as a laboratory sign of lipolysis. The result was therefore antilipogenic, not a broad demonstration of increased fat burning.

Another study isolated fat cells from genetically obese Zucker rats. Zucker rats are a laboratory strain with a mutation that disrupts normal appetite and weight regulation. HGH 177-191 changed glucose transport into those cells. This may help explain the earlier tissue observations, but it remains a rat-cell result.

In 1994, researchers treated obese mice with HGH 177-191 and reported less cumulative weight gain and lower fat mass. The paper did not turn the fragment into a human treatment. Genetically obese mice differ from people in the cause of obesity, metabolism, scale and controlled living conditions.

Online accounts often compress these studies into the sentence that HGH Fragment 176-191 burns fat without growth-hormone side effects. That sentence changes the molecule, the species, the outcome and the certainty. The original record does not support it.

What did AOD-9401 and AOD-9604 add?

AOD-9401 was a development name for cyclic HGH 177-191. Animal and tissue studies reported changes in fat metabolism and weight gain. AOD-9604 added a tyrosine to the front of that sequence and was developed as a more stable anti-obesity candidate.

Studies in obese mice reported less weight gain and more fat oxidation after AOD-9604. Fat oxidation means using fatty acids as fuel. These experiments helped justify human development.

The human programme did not confirm a useful obesity treatment. A Phase 2b trial is a middle-stage clinical study intended to examine dose, effectiveness and safety in a larger patient group before a confirmatory Phase 3 programme. The AOD-9604 Phase 2b programme did not establish the planned weight-loss effect, and development for obesity stopped.

FDA's current compounding safety page discusses AOD-9604, not HGH 176-191. FDA notes limited safety information, possible immune reactions, peptide-related impurities and uncertainty around reported serious adverse events. The nomination for compounding was withdrawn. This is relevant to the related-molecule context but should not be presented as a direct FDA assessment of exact HGH 176-191.

A failed related programme does not prove that HGH 176-191 has no biological activity. It shows why animal weight findings and structural similarity are not enough to support a human fat-loss claim.

Is there direct human evidence for HGH Fragment 176-191?

We did not locate a controlled human clinical trial of the exact 16-residue HGH 176-191 sequence in PubMed or the current ClinicalTrials.gov record reviewed for this guide.

That means there is no direct clinical basis for estimating:

  • Whether it changes body weight or body fat in people.
  • Whether it changes growth hormone, IGF-1, glucose, insulin or HbA1c.
  • How the human body absorbs, distributes, breaks down or removes it.
  • Which short-term adverse effects are common.
  • Whether repeated exposure produces antibodies or organ effects.
  • Whether any administration level is effective or tolerable.

Absence of a located trial is not proof that no person has ever received the fragment. It means the claims cannot be grounded in a published controlled human evidence base.

Reports from users, clinics or vendors are not substitutes. They lack random assignment, a reliable comparison group, verified products and systematic outcome collection. Weight can change because of food intake, activity, water, other medicines and measurement timing.

Our research methodology gives greater weight to direct controlled human evidence than to a related molecule, animal model or personal report.

What about laboratory cancer research?

A 2022 paper combined HGH Fragment 176-191 with doxorubicin-loaded chitosan nanoparticles in MCF-7 breast-cancer cells. Doxorubicin is a chemotherapy medicine. Chitosan is a material derived from chitin, a structural substance found in shellfish shells and other natural sources. A nanoparticle is a very small engineered carrier.

MCF-7 is a human breast-cancer cell line grown in a laboratory. The researchers measured cell toxicity and used computer modelling to explore possible molecular interactions. The combination increased measured toxicity to the cultured cells under the study conditions.

This was not a trial in people or an established cancer treatment. Cells in a dish do not reproduce absorption, immune responses, tumour blood supply, organ toxicity or interactions with a complete treatment plan. The work also does not show that taking HGH Fragment 176-191 alone prevents or treats cancer.

This section is included because the paper may appear in search results for the exact fragment. Its relevance is experimental drug-delivery research, not clinical oncology.

What administration levels appeared in the preclinical studies?

There are no direct human trial levels for the exact fragment to document. The table records selected animal and laboratory conditions only. It is not personal dosing, preparation or administration guidance.

StudyModelDocumented research exposureMain observation
1978 C-terminal-fragment studyNormal ratsOne exposure of 5 nanomoles per kilogram for HGH 176-191 and related fragmentsBrief rise in glucose, longer rise in insulin and reduced insulin sensitivity
1979 synthesis studyAnimal glucose assaysSynthetic HGH 177-191 and shorter fragments in experimental assaysInsulin-antagonistic activity depended on sequence length; reduced form also active
1993 fat-pad studyRat fat tissue after experimental treatmentHGH 177-191 under the paper's animal and tissue conditionsReduced fat synthesis; no significant rise in measured fat breakdown
1994 obese-mouse studyGenetically obese miceRepeated HGH 177-191 exposure under controlled animal conditionsLess cumulative weight gain and lower fat mass
2022 nanoparticle studyMCF-7 breast-cancer cellsLaboratory concentrations of fragment and doxorubicin-loaded nanoparticlesGreater cell toxicity in vitro

Nanomoles per kilogram count molecules relative to animal body weight. Cell-culture concentrations describe material placed in a laboratory dish. Neither can be converted safely into a human administration level. Differences in species, route, chemical form and study purpose prevent that calculation.

Does HGH Fragment 176-191 burn fat?

Direct human evidence does not establish fat loss.

The supporting chain usually combines four separate records:

  1. HGH 176-191 changed glucose and insulin in rats in 1978.
  2. HGH 177-191 reduced fat synthesis in rat tissue in 1993.
  3. HGH 177-191 reduced weight gain in obese mice in 1994.
  4. Modified AOD fragments produced additional animal findings, but human obesity development did not establish efficacy.

This chain does not contain a successful controlled human trial of HGH 176-191. It also does not show that the exact fragment increases the breakdown of stored fat. The 1993 paper specifically found no significant lipolytic effect in its glycerol-release measure.

Fat loss in a person would need to be shown with a defined product, randomised comparison, adequate duration and validated measures such as body weight, waist circumference or imaging of fat compartments. Visceral fat is fat around internal abdominal organs and requires a reliable measurement method.

Does it preserve muscle while reducing fat?

There is no direct clinical evidence for this combined claim.

The fragment is often promoted as keeping the fat-related part of growth hormone while removing its growth effects. That is a hypothesis derived from fragment research, not a demonstrated human outcome. The exact peptide has not been shown to preserve lean mass, strength or function during weight loss.

Muscle preservation requires more than a scale reading. A study would need body-composition methods capable of separating lean tissue from water, together with strength and physical-function tests. It would also need to control food intake, protein intake, activity and other medicines.

The fact that HGH Fragment 176-191 is shorter than growth hormone does not establish that it is free from glucose, heart, immune or tissue effects.

Does it improve recovery or heal injuries?

No direct evidence supports a recovery or injury-healing use.

The peptide's relationship to growth hormone can make the claim sound plausible, but no controlled human trial has shown faster healing of tendon, ligament, muscle, bone or skin. The older research focused mainly on metabolic measurements in rats and isolated tissues.

Recovery is also an imprecise term. A meaningful study would need a defined injury, treatment comparison, imaging or tissue-healing measure, pain and function outcomes, return-to-activity criteria and follow-up for re-injury.

What are the main safety uncertainties?

The absence of direct human trials leaves safety largely undefined. Potential concerns come from the exact fragment's animal findings, the wider fragment record and product quality.

  • Glucose and insulin: The direct 1978 rat study found higher glucose, higher insulin and reduced insulin sensitivity. Insulin sensitivity describes how effectively insulin helps move glucose from blood into cells. Human effects are unknown, not proven absent.
  • Immune reactions: A synthetic peptide, aggregate or impurity may trigger antibodies or an allergic response. Antibodies can bind the administered peptide and could potentially cross-react with related natural structures.
  • Disulphide and oxidation state: Linear, cyclic, mispaired and aggregated forms may behave differently. A label may not disclose their proportions.
  • Product contamination: Microorganisms, endotoxins, particles, residual solvents or inaccurate concentration can create harms separate from the peptide's intended biology.
  • Unknown organ effects: There are no adequate human data for the heart, liver, kidneys, pancreas, nervous system or reproductive system.
  • Unknown interactions: The fragment has not been systematically studied with diabetes medicines, weight-management medicines, growth hormone, secretagogues or other peptides.
  • Long-term uncertainty: There are no controlled data on repeated exposure, antibodies, cancer-related outcomes, fertility or pregnancy.

An online statement that the fragment avoids the side effects of full growth hormone is not supported by direct evidence. Different does not mean harmless. It means the benefit and risk profile must be established separately.

Could it affect glucose regulation?

This is one of the clearest unanswered safety questions.

The exact HGH 176-191 sequence caused a short-lived glucose rise and reduced insulin sensitivity in rats. Related fragments changed insulin release, glucose transport and glycogen enzymes in other preclinical experiments.

These results do not prove that people would develop high blood glucose or diabetes. Species and exposure differences matter. They do mean it is inaccurate to claim that the C-terminal fragment has been cleanly separated from growth hormone's effects on glucose.

A human study would need fasting glucose, insulin, HbA1c and perhaps an oral glucose-tolerance test. An oral glucose-tolerance test measures the body's response after a standard glucose drink. Researchers would also need to consider starting body weight, diabetes risk and medicines that change glucose.

Without those data, neither metabolic safety nor benefit can be quantified.

Is HGH Fragment 176-191 approved as a medicine?

No. It is not an FDA-approved medicine, and we did not identify a current EMA-authorised product containing the exact fragment.

FDA approval applies to a defined product, manufacturer, formulation and use. A peptide appearing in a chemical database or research paper is not approval. A patent is also not approval.

Compounded drugs are not FDA approved. Compounding is the preparation of a medicine for a patient under particular legal conditions. FDA does not verify a compounded drug's safety, effectiveness and quality before marketing in the same way it reviews an approved product.

FDA's current safety page discusses AOD-9604, which is a related but different modified fragment. It does not list exact HGH 176-191. That absence is not clearance, approval or a finding of safety.

Is HGH Fragment 176-191 prohibited in sport?

Yes. The World Anti-Doping Agency, commonly called WADA, explicitly names HGH 176-191 among growth hormone fragments prohibited at all times. The same section names AOD-9604.

For athletes covered by the World Anti-Doping Code, at all times means in and out of competition. The rule does not depend on FDA approval, product labelling or whether a seller describes the material as a research chemical.

Athletes are responsible for prohibited substances found in their samples. Anti-doping rules and therapeutic-use-exemption requirements can change, so current official information should be checked.

What product-quality questions matter?

The label HGH Fragment 176-191 does not prove identity. A meaningful quality assessment would ask:

  • Does the material contain the 16-residue sequence beginning with phenylalanine?
  • Has it been confused with 15-residue HGH 177-191 or tyrosine-starting AOD-9604?
  • Is the peptide in the intended disulphide-bonded form?
  • How much reduced, mispaired, dimerised or aggregated peptide is present?
  • Which salt and counterions are present?
  • Are deletion sequences, oxidation products and residual solvents controlled?
  • Does the container hold the stated amount?
  • Has stability been studied under the stated conditions?
  • For an injectable product, have sterility, endotoxin and particle controls been validated?

Mass spectrometry should be able to distinguish the main molecular masses of HGH 176-191, HGH 177-191 and AOD-9604, but the method needs suitable interpretation and reference material. HPLC can separate some impurities, but one purity percentage does not prove disulphide arrangement, sterility or concentration.

The name “fragment” can make the molecule sound simple. Sixteen chemical coupling steps, two cysteines and a controlled oxidation step create several opportunities for unwanted forms.

How does HGH Fragment 176-191 compare with full growth hormone and AOD-9604?

FeatureHGH Fragment 176-191Full human growth hormoneAOD-9604
Size16 amino acids191 amino acids16 amino acids
First residuePhenylalanine corresponding to position 176Phenylalanine at position 1 of mature growth hormoneAdded tyrosine before HGH 177-191
Direct human clinical evidenceNo controlled trial locatedExtensive condition-specific evidence for approved productsHuman obesity programme did not establish efficacy
Main research recordOlder rat glucose and insulin researchGrowth disorders, deficiency and other approved indicationsAnimal metabolism and unsuccessful obesity development
FDA statusNot approvedDefined recombinant products are approved for specific usesNot approved as an obesity medicine
Anti-doping statusProhibitedProhibited without an applicable exemptionProhibited

Approved recombinant growth hormone products should not be treated as evidence for the fragment. Recombinant means made by engineered living cells. Those products have defined manufacturing, clinical trials, labels, contraindications and monitoring requirements.

AOD-9604 should not be used as a substitute name for HGH 176-191. Its extra tyrosine changes the sequence, and its development record belongs to that molecule.

What claims are not established?

Current evidence does not establish HGH Fragment 176-191 for:

  • Producing clinically useful fat loss or weight loss.
  • Increasing fat breakdown in people.
  • Preserving muscle during dieting.
  • Building muscle, increasing strength or improving performance.
  • Healing tendon, ligament, muscle, bone or skin injuries.
  • Improving recovery, sleep, energy or wellbeing.
  • Raising or optimising growth hormone or IGF-1.
  • Avoiding the glucose effects associated with growth hormone.
  • Treating diabetes, insulin resistance or fatty liver disease.
  • Treating cancer or improving chemotherapy.
  • Providing the benefits of growth hormone without its risks.

Some claims are based on real papers. The problem is that the papers used a different fragment, a different species, isolated cells or a modified AOD molecule. Evidence must stay attached to the molecule and model actually studied.

What would stronger evidence require?

The first step would be exact identity. Researchers would need to specify sequence, disulphide state, salt, impurities, aggregation, stability and, where relevant, sterility and endotoxin control.

A first-in-human study would begin with cautious exposure in a closely monitored clinical setting. First-in-human means the first formal administration of a defined investigational product to people. It would need pharmacokinetics, which describes absorption, distribution, breakdown and removal, and pharmacodynamics, which describes biological effects.

Because of the animal findings, early monitoring should include glucose, insulin, HbA1c and perhaps glucose-tolerance testing. Growth hormone and IGF-1 should be measured rather than assumed to be unaffected. Researchers should look for antibodies, allergic reactions, heart effects and changes in liver or kidney laboratory tests.

A weight-management trial would then need random assignment, a suitable placebo, adequate duration and a predefined primary outcome. Random assignment uses chance to reduce systematic differences between groups. A placebo is an inactive comparison that helps separate treatment effects from expectation and ordinary change.

Body weight alone would not support a muscle-preservation claim. Trials would need validated body-composition measures, waist, imaging where appropriate, strength, function and adverse events. Food intake and physical activity would need to be measured because they strongly affect outcomes.

The trial would also need enough participants to detect useful effects and common harms. Longer follow-up would be required for glucose control, antibodies, weight regain and delayed adverse events.

Until that programme exists, a detailed mechanism story cannot replace missing human evidence.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What does HGH Fragment 176-191 mean?

It means a peptide copying amino-acid positions 176 through 191 at the end of the 191-amino-acid human growth hormone protein.

How many amino acids are in HGH Fragment 176-191?

It contains 16 residues. The first is phenylalanine and the last is phenylalanine.

Is HGH Fragment 176-191 human growth hormone?

No. It is a small structural fragment of the much larger hormone and cannot reproduce its complete folded shape or evidence record.

Does it release growth hormone?

It is not an established growth hormone secretagogue, and no direct human evidence shows that it raises growth hormone or IGF-1.

Is HGH 176-191 the same as HGH 177-191?

No. HGH 176-191 has an additional phenylalanine at its beginning. Many fat-metabolism papers tested HGH 177-191 instead.

Is HGH Fragment 176-191 the same as AOD-9604?

No. AOD-9604 is Tyr-HGH 177-191. It begins with an added tyrosine, while HGH 176-191 begins with the natural phenylalanine at position 176.

Does HGH Fragment 176-191 burn fat?

No controlled human trial has established fat loss. The commonly cited findings come mainly from rat tissue, obese mice and related but different fragments.

Did the rat research show increased fat breakdown?

The 1993 HGH 177-191 paper found reduced fat synthesis but no significant increase in glycerol release, its measure of fat breakdown.

What did the direct HGH 176-191 rat study find?

It found a brief rise in blood glucose, a longer rise in insulin and reduced insulin sensitivity after one experimental exposure. It did not test human fat loss.

Has HGH Fragment 176-191 been tested in people?

We did not locate a published controlled human clinical trial of the exact 16-residue sequence. The human AOD-9604 record belongs to a different molecule.

Does it preserve muscle?

There is no direct clinical evidence that it preserves lean mass, strength or function during weight loss.

Does it heal injuries?

No controlled human evidence shows faster healing of tendon, ligament, muscle, bone or skin.

Is it safer than growth hormone?

That has not been established. The fragment has different biology, but it lacks the direct human trials needed to define common and long-term risks.

Is HGH Fragment 176-191 FDA approved?

No. It is not an FDA-approved medicine, and we did not identify a current EMA-authorised product containing it.

Are the administration levels in this guide recommendations?

No. The numbers document animal or laboratory experiments. They cannot be converted into personal human dosing or administration guidance.

Is HGH Fragment 176-191 prohibited in sport?

Yes. WADA explicitly lists HGH 176-191 among growth hormone fragments prohibited at all times.

RESEARCH AND MEDICAL NOTICE

This guide explains published research and its limits. It does not recommend HGH Fragment 176-191, provide a dose, describe preparation or administration, propose a cycle or advise combining it with another compound. The experimental levels reported above belong only to the cited animal and laboratory studies.

RESEARCH LIBRARY

Sources

Chemistry and identitypubchem.ncbi.nlm.nih.gov
PubChem: somatotropin (176-191)Open source →
Chemistry and identityPubMed
Conformation of cyclic HGH 177-191Open source →
Chemistry and identityPubMed
Review of AOD-9604 chemistry and developmentOpen source →
Direct and related fragment researchPubMed
HGH 176-191 and related fragments in normal ratsOpen source →
Direct and related fragment researchPubMed
Synthesis and activity of HGH 177-191 and shorter fragmentsOpen source →
Direct and related fragment researchPubMed
Mechanism of hyperglycaemic action in related fragmentsOpen source →
Direct and related fragment researchPubMed
HGH 177-191 and liver glycogen metabolismOpen source →
Direct and related fragment researchPubMed
HGH 177-191 and muscle glycogen synthaseOpen source →
Direct and related fragment researchPubMed
C-terminal fragments and insulin release from rat isletsOpen source →
Direct and related fragment researchPubMed
C-terminal fragments and glucose oxidation in rat isletsOpen source →
Direct and related fragment researchPubMed
Shortened HGH 177-191 fragments and insulin-antagonistic activityOpen source →
Fat metabolism and obesity researchPubMed
HGH 177-191 and fat synthesis in rat tissueOpen source →
Fat metabolism and obesity researchPubMed
HGH 177-191 and glucose transport in rat fat cellsOpen source →
Fat metabolism and obesity researchPubMed
HGH 177-191 in obese miceOpen source →
Fat metabolism and obesity researchPubMed
AOD-9401 and lipid metabolism in obese miceOpen source →
Fat metabolism and obesity researchPubMed
AOD-9604, fat oxidation and weight in obese miceOpen source →
Fat metabolism and obesity researchPubMed
AOD-9604 and beta-3 adrenergic signalling in miceOpen source →
Other laboratory researchPubMed
HGH Fragment 176-191 with doxorubicin nanoparticles in breast-cancer cellsOpen source →
Evidence searchesClinicalTrials.gov
ClinicalTrials.gov search for HGH Fragment 176-191Open source →
Evidence searchesPubMed
PubMed search for HGH Fragment 176-191Open source →
Regulatory and anti-doping sourcesFDA
FDA: human drug compoundingOpen source →
Regulatory and anti-doping sourcesFDA
FDA: AOD-9604 and other bulk substances with identified concernsOpen source →
Regulatory and anti-doping sourcesWorld Anti-Doping Agency
World Anti-Doping Agency: 2026 Prohibited ListOpen source →

Research reviewed through September 2026.